BeiGene
BGNE
#855
Rank
A$36.58 B
Marketcap
$319.73
Share price
0.61%
Change (1 day)
17.67%
Change (1 year)
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

Earnings for BeiGene (BGNE)

Earnings in 2024 (TTM): -A$1.3 Billion

According to BeiGene 's latest financial reports the company's current earnings are A$3.31 Billion. In 2023 the company made an earning of -A$1.87 Billion, an increase over its 2022 earnings that were of -A$2.77 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for BeiGene from 2015 to 2024

Annual earnings

Year Earnings Change
2024 (TTM) -A$1.3 Billion-30.4%
2023 -A$1.87 Billion-32.52%
2022 -A$2.77 Billion24.39%
2021 -A$2.23 Billion-13.21%
2020 -A$2.57 Billion72.69%
2019 -A$1.49 Billion36.01%
2018 -A$1.1 Billion616.83%
2017 -A$0.16 Billion-15.24%
2016 -A$0.18 Billion107.91%
2015 -A$86.3 Million

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
-A$28.05 Million-97.92%๐Ÿ‡บ๐Ÿ‡ธ USA
-A$0.19 Billion-86.49%๐Ÿ‡บ๐Ÿ‡ธ USA